Isolation of monoclonal immunoglobulin from plasma of patients with multople myeloma using affinity chromatography

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F02%3A00006850" target="_blank" >RIV/00216224:14110/02:00006850 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Isolation of monoclonal immunoglobulin from plasma of patients with multople myeloma using affinity chromatography
Original language description
Multiple myeloma is characterized by the proliferation of a malignant plasma cell clone and accounts for approximately 10% of hematological malignancies. High-dose chemotherapy with autologous transplantation has improved the survival of patients with myeloma, hovewer, relapse is inevitable (1,2). Recent research has targeted the minimal residual disease. One of the therapeutical options is this setting is immunotherapy using specific tumor antigen as a vaccine. The idiotype of myeloma immunoglobulin (Id protein) is specifically expressed by malignant cells and can be used as a tumor antigen with the aim to induce cytotoxic T-lymphocyte response against myeloma cells (3,4,5,6). For purification of Id protein from plasma of relapsed IgG myeloma patientswho were before reinduction treatment, plasma was precipitated with a saturated solution of ammonium sulfate. After precipitation and dialysis in saline at pH 7.3 to remove ammonium sulfate, the Id protein was separated on protein G immo
Czech name
—
Czech description
—

Project
<a href="/en/project/NC6763" target="_blank" >NC6763: Use of monoclonal immunoglobulin for preparation of antitumor vaccine in patients with multiple myeloma</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2002
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)